Pancreatic Cancer Research

ResearcherUniversità Campus Bio-MedicoActive in the last 2 years

Damiano D. Caputo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7058-1945; OpenAlex author ID A5019046789. Sources: ClinicalTrials.gov.

Their work

Papers
37 (first author 5, last author 10)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers, 1 trial · 2021: 4 papers · 2022: 4 papers · 2023: 7 papers · 2024: 5 papers · 2025: 4 papers · 2026: 5 papers

Papers 37

  1. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  2. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  3. Plasma Protein Corona Fingerprinting Across Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma: A Comparative Proof-of-Concept Study. Last author DOI 10.3390/cancers18203275↗
  4. Exploratory PET/CT Radiomics for Predicting Early Progression in Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/diagnostics16101499↗
  5. Pancreatic Steatosis as a Risk Phenotype for Pancreatic Ductal Adenocarcinoma: A Narrative Review. Last author DOI 10.3390/medicina62040729↗
  6. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  7. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  8. Nanoparticle-protein corona enhances accuracy of Ca-19.9-based pancreatic cancer classification. First author DOI 10.1039/d4nr02435d↗
  9. Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma: Aligning Guideline Recommendations with Real-World Evidence. Last author DOI 10.3390/cancers17183085↗
  10. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  11. The impact of intensified staging and combined therapies in locally advanced pancreatic cancer: a secondary analysis of prospective studies. Co-author DOI 10.1097/js9.0000000000000755↗
  12. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  13. The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers. Co-author DOI 10.1186/s13046-024-03117-5↗
  14. Novel Biomarkers in Pancreatic Cancer. Last author DOI 10.3390/cancers16030628↗
  15. Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection. Co-author DOI 10.1097/js9.0000000000000558↗
  16. Coupling magnetic levitation of graphene oxide–protein complexes with blood levels of glucose for early detection of pancreatic adenocarcinoma First author DOI 10.1186/s12645-023-00170-1↗
  17. Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review. Co-author DOI 10.21037/jgo-22-1034↗
  18. Stratifying Risk for Pancreatic Cancer by Multiplexed Blood Test. Last author DOI 10.3390/cancers15112983↗
  19. Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going. Last author DOI 10.3390/jcm12113677↗
  20. Hot topics in pancreatic cancer management. Co-author DOI 10.4240/wjgs.v15.i2.121↗
  21. Role of preoperative sarcopenia in predicting postoperative complications and survival after pancreatoduodenectomy for pancreatic cancer. Last author PMID 36810297↗
  22. Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives. Last author DOI 10.3390/biomedicines10092091↗
  23. Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins. Co-author DOI 10.3390/cancers14194658↗
  24. Nanotechnology Meets Oncology: A Perspective on the Role of the Personalized Nanoparticle-Protein Corona in the Development of Technologies for Pancreatic Canc… Co-author DOI 10.3390/ijms231810591↗
  25. Role of Neoplastic Markers in Pancreatic Adenocarcinoma. Last author DOI 10.3390/jcm11216509↗
  26. Efficient pancreatic cancer detection through personalized protein corona of gold nanoparticles. First author DOI 10.1116/6.0000540↗
  27. CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Last author DOI 10.3389/fonc.2021.690580↗
  28. Detection of Pancreatic Ductal Adenocarcinoma by Ex Vivo Magnetic Levitation of Plasma Protein-Coated Nanoparticles. Co-author DOI 10.3390/cancers13205155↗
  29. Nanotechnology and pancreatic cancer management: State of the art and further perspectives. Co-author DOI 10.4251/wjgo.v13.i4.231↗
  30. Nanoparticle-enabled blood tests for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.11.030↗
  31. Personalized Graphene Oxide-Protein Corona in the Human Plasma of Pancreatic Cancer Patients. Co-author DOI 10.3389/fbioe.2020.00491↗
  32. A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers12082016↗
  33. Synergistic Analysis of Protein Corona and Haemoglobin Levels Detects Pancreatic Cancer. Co-author DOI 10.3390/cancers13010093↗
  34. Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer. First author DOI 10.3390/pharmaceutics11010031↗
  35. Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study. Co-author DOI 10.1016/j.pan.2018.06.002↗
  36. Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic canc… Co-author DOI 10.1038/srep45845↗
  37. Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients. First author DOI 10.1016/j.colsurfb.2014.10.008↗

Trials 1

  1. Validations of New cut-of for the Stratification of Postoperative Complications,Drains Management Principal investigator NCT04380506↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Coppola · 22 shared papers, 2014–2026 · strength 3.61
  2. Vincenzo La Vaccara · 13 shared papers, 2021–2026 · strength 2.83
  3. Giulio Caracciolo · 16 shared papers, 2014–2025 · strength 2.57
  4. Daniela Pozzi · 15 shared papers, 2014–2025 · strength 2.50
  5. Roberto Cammarata · 10 shared papers, 2022–2026 · strength 2.30
  6. Alessandro Coppola · 12 shared papers, 2020–2024 · strength 2.14
  7. Erica Quagliarini · 9 shared papers, 2020–2025 · strength 1.59
  8. Luca Digiacomo · 9 shared papers, 2018–2025 · strength 1.26
  9. Sara Ramella · 7 shared papers, 2017–2026 · strength 1.08
  10. Michele Fiore · 7 shared papers, 2017–2026 · strength 1.08
  11. Sara Elsa Aita · 2 shared papers, 2026 · strength 0.62
  12. Sara Palchetti · 4 shared papers, 2018–2021 · strength 0.44
  13. Heinz Wilfried Amenitsch · 2 shared papers, 2021–2025 · strength 0.36
  14. Riccardo Di Santo · 3 shared papers, 2020–2022 · strength 0.36
  15. Rolando Maria D’Angelillo · 2 shared papers, 2017–2024 · strength 0.24
  16. Carla Mottini · 1 shared paper, 2024 · strength 0.20
  17. Alfredo Budillon · 1 shared paper, 2024 · strength 0.20
  18. Maria Serena Roca · 1 shared paper, 2024 · strength 0.20
  19. Giovanni Blandino · 1 shared paper, 2024 · strength 0.20
  20. Giulia Piaggio · 1 shared paper, 2024 · strength 0.20
  21. Christian P. Pilarsky · 1 shared paper, 2024 · strength 0.20
  22. Francesco Giovinazzo · 1 shared paper, 2023 · strength 0.18
  23. Sergio Valeri · 1 shared paper, 2017 · strength 0.07
  24. Lucio Trodella · 1 shared paper, 2017 · strength 0.07
  25. Valentina Colapicchioni · 1 shared paper, 2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.